

**ASSAY ADVANTAGE (VACZINE ANALYTICS) LTD**

**Company Registration Number:  
05807728 (England and Wales)**

**Abbreviated (Unaudited) Accounts**

**Period of accounts**

**Start date: 01st April 2013**

**End date: 31st March 2014**

SUBMITTED

---

# **ASSAY ADVANTAGE (VACZINE ANALYTICS) LTD**

## **Company Information for the Period Ended 31st March 2014**

<b>Director:</b>	Dr R. Savopoulos Dr J.W. Savopoulos
<b>Registered office:</b>	Warren House Bells Hill  Bishop's Stortford Hertfordshire CM23 2NN
<b>Company Registration Number:</b>	05807728 (England and Wales)

---

# ASSAY ADVANTAGE (VACZINE ANALYTICS) LTD

## Abbreviated Balance sheet As at 31st March 2014

	Notes	2014 £	2013 £
<b>Fixed assets</b>			
Intangible assets:	2	300	300
Tangible assets:	3	287	573
<b>Total fixed assets:</b>		<u>587</u>	<u>873</u>
<b>Current assets</b>			
Debtors:		49,364	39,648
Cash at bank and in hand:		289,729	275,127
<b>Total current assets:</b>		<u>339,093</u>	<u>314,775</u>
<b>Creditors</b>			
Creditors: amounts falling due within one year		34,064	41,178
<b>Net current assets (liabilities):</b>		<u>305,029</u>	<u>273,597</u>
<b>Total assets less current liabilities:</b>		305,616	274,470
<b>Total net assets (liabilities):</b>		<u><u>305,616</u></u>	<u><u>274,470</u></u>

The notes form part of these financial statements

---

# ASSAY ADVANTAGE (VACZINE ANALYTICS) LTD

## Abbreviated Balance sheet As at 31st March 2014 continued

	Notes	2014 £	2013 £
<b>Capital and reserves</b>			
Called up share capital:	4	1,000	1,000
Profit and Loss account:		304,616	273,470
<b>Total shareholders funds:</b>		<u>305,616</u>	<u>274,470</u>

For the year ending 31 March 2014 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the Financial Reporting Standard for Smaller Entities (effective 2008).

The financial statements were approved by the Board of Directors on 15 December 2014

### SIGNED ON BEHALF OF THE BOARD BY:

Name: Dr R. Savopoulos

Status: Director

The notes form part of these financial statements

---

# **ASSAY ADVANTAGE (VACZINE ANALYTICS) LTD**

## **Notes to the Abbreviated Accounts for the Period Ended 31st March 2014**

### **1. Accounting policies**

#### **Basis of measurement and preparation of accounts**

The financial statements have been prepared under the historical cost convention, modified to include the revaluation of certain fixed assets, and in accordance with the Financial Reporting Standard for Smaller Entities (effective April 2008).

#### **Turnover policy**

The turnover shown in the profit and loss account represents amounts invoiced during the year, exclusive of Value Added Tax.

#### **Tangible fixed assets depreciation policy**

Depreciation is calculated so as to write off the cost of an asset, less its estimated residual value, over the useful economic life of that asset as follows: Plant and machinery etc - 33% on cost

---

# ASSAY ADVANTAGE (VACZINE ANALYTICS) LTD

## Notes to the Abbreviated Accounts for the Period Ended 31st March 2014

### 2. Intangible assets

	Total
<b>Cost</b>	<b>£</b>
At 01st April 2013:	300
	<u>300</u>
<b>Net book value</b>	<b>£</b>
At 31st March 2014:	<u>300</u>
At 31st March 2013:	<u>300</u>

---

# ASSAY ADVANTAGE (VACZINE ANALYTICS) LTD

## Notes to the Abbreviated Accounts for the Period Ended 31st March 2014

### 3. Tangible assets

	Total
<b>Cost</b>	<b>£</b>
At 01st April 2013:	4,770
At 31st March 2014:	4,770
<b>Depreciation</b>	
At 01st April 2013:	4,197
Charge for year:	286
At 31st March 2014:	4,483
<b>Net book value</b>	
At 31st March 2014:	287
At 31st March 2013:	573

---

# ASSAY ADVANTAGE (VACZINE ANALYTICS) LTD

## Notes to the Abbreviated Accounts for the Period Ended 31st March 2014

### 4. Called up share capital

Allotted, called up and paid

Previous period			<b>2013</b>
Class	Number of shares	Nominal value per share	Total
Ordinary shares:	1,000	1.00	<b>1,000</b>
Total share capital:			<b>1,000</b>
Current period			<b>2014</b>
Class	Number of shares	Nominal value per share	Total
Ordinary shares:	1,000	1.00	<b>1,000</b>
Total share capital:			<b>1,000</b>

---

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.



